Brazil Dermatological Therapeutics Market Size & Outlook, 2025-2033
Brazil Dermatological Therapeutics Market Insights
- As per Reed Intelligence insights, the Brazil Dermatological Therapeutics Market stood at USD 784.7 Million in 2024 and is anticipated to grow to USD 1007.61 Million by 2033.
- The Brazil market is expected to advance at a CAGR of 2.8% from 2025 through 2033.
- In 2024, Psoriasis accounted for the highest share of the Application market size.
- During the forecast period, Skin Infections is set to register the highest growth, making it the most lucrative Application segment.
![Brazil Dermatological Therapeutics Market Size, Share & Growth Report By [2033]](https://reedintelligence.com/uploads/charts/brazil-dermatological-therapeutics-market-brazil-application-24491.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Brazil accounted for 3.49% of the global Dermatological Therapeutics Market size in 2024.
- By 2033, United States is expected to remain the top global market in terms of size.
- Within LATAM, Brazil is forecasted to dominate the regional Dermatological Therapeutics Market size by 2033.
- Chile will be the fastest-growing market in LATAM, projected to achieve USD 188.17 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 784.7 Million |
| Market Size In 2033 | USD 1007.61 Million |
| Largest segment | Psoriasis |
| Units | Revenue in USD Million |
| CAGR | 2.8% (2025-2033) |
| Segmnetation Covered | |
| Application |
|
| Route of Administration |
|
| Drug Class |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Brazil Dermatological Therapeutics Market Application 2025-2033 (USD Million)
| Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | XX.x | XX.x | XX.x | 310.82 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Acne | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Eczema | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Skin Infections | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Skin Cancer | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Brazil Dermatological Therapeutics Market Route of Administration 2025-2033 (USD Million)
| Route of Administration | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Topical | XX.x | XX.x | XX.x | 414.94 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Systemic | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Injectable | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Brazil Dermatological Therapeutics Market Drug Class 2025-2033 (USD Million)
| Drug Class | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corticosteroids | XX.x | XX.x | XX.x | 289.24 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Antibiotics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Retinoids | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Biologics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Antifungals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
